POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
Jane F. ApperleyImperial College London, London, United KingdomJörge E. CortesRussian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian FederationElias JabbourLLC Hema, Moscow, Russian FederationAndreas HochhausOregon Health Science University, Portland, USATimothy P. HughesMD Anderson, Houston, USACharles ChuahEnliven Therapeutics, Boulder, USAHugues de LavalladeDar El-Salam Cancer Center, Cairo, EgyptMichael W. DeiningerVersiti Blood Research Institute, Milwaukee, USAJeffrey H. LiptonPrincess Margaret Cancer Centre, Toronto, CanadaElza LomaiaMemorial Sloan Kettering Cancer Center, New York, USALori J. ManessUniversity of Nebraska Medical Center, Omaha, USAMichael J. MauroImperial College London, London, United KingdomJames A. McCloskeyJohn Theurer Cancer Center at Hackensack Meridian Health, Hackensack, USABeatriz MoiraghiHospital Jose Maria Ramos Mejía, Buenos Aires, ArgentinaCarolina PavlovskyFundaleu, Buenos Aires, ArgentinaChristine RojasCentro de Investigaciones Clinicas Vina del Mar, Valparaíso, ChilePhilippe RousselotCentre Hospitalier de Versailles Université de Versailles Saint-Quentin-en-Yvelines, Paris, FranceTomasz SachaJagiellonian University Hospital in Krakow, Krakow, PolandMoshe TalpazMichigan Center for Translational PathologyAnna TurkinaNational Medical Research Center for Hematology, Moscow, Russian FederationMaria Undurraga SuttonHospital del Salvador, Santiago, ChileXiaowei RenTakeda Development Center Americas, Inc., Lexington, USAAlexander VorogTakeda Development Center Americas, Inc., Lexington, USAGianantonio RostiIRST/IRCCS "Dino Amadori", Meldola (FC), Italy
ABI
Annotatsiya
Annotatsiya mavjud emas.
Mavzular
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos0 ta foydalanilgan manba